Stock SAR SAREUM HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sareum Holdings plc

Equities

SAR

GB00BMC3RJ87

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:12 2024-05-02 am EDT 		5-day change 1st Jan Change
25.25 GBX -7.34% Intraday chart for Sareum Holdings plc -24.63% -57.56%
Apr. 23 Sareum Issues Shares to Settle Facility with RiverFort MT
Apr. 19 Sareum falls as issues shares to RiverFort Global AN

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 13.36 17.02 191.6 137.8 85.09 26.98 - -
Enterprise Value (EV) 1 13.36 17.02 191.6 133.6 84.09 28.43 29.06 49.45
P/E ratio -8.7 x -17.5 x -115 x -63.3 x -26.6 x -5.35 x -6.95 x 0.66 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - 490 x - 0.63 x
EV / Revenue - - - - - 517 x - 1.15 x
EV / EBITDA - - - -51.8 x -20.7 x -9.01 x -8.95 x 1.45 x
EV / FCF - - - - -25.7 x -12.4 x -14.5 x 2.42 x
FCF Yield - - - - -3.88% -8.09% -6.88% 41.3%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 61,427 64,835 66,657 68,069 68,069 106,839 - -
Reference price 2 0.2175 0.2625 2.875 2.025 1.250 0.2525 0.2525 0.2525
Announcement Date 10/15/19 10/12/20 10/25/21 10/24/22 10/9/23 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 0.055 - 43.15
EBITDA 1 - - - -2.578 -4.065 -3.154 -3.248 33.99
EBIT 1 -1.686 - -1.718 -2.58 -4.066 -4.154 -3.2 34
Operating Margin - - - - - -7,552.73% - 78.8%
Earnings before Tax (EBT) 1 -1.682 - -1.718 -2.579 -4.025 -4.146 -3.2 34
Net income 1 -1.452 -0.9859 -1.5 -2.172 -3.192 -3.396 -2.6 27.2
Net margin - - - - - -6,175.45% - 63.04%
EPS 2 -0.0250 -0.0150 -0.0250 -0.0320 -0.0470 -0.0472 -0.0363 0.3800
Free Cash Flow 1 - - - - -3.267 -2.3 -2 20.4
FCF margin - - - - - -4,181.82% - 47.28%
FCF Conversion (EBITDA) - - - - - - - 60.02%
FCF Conversion (Net income) - - - - - - - 75%
Dividend per Share 2 - - - - - - - -
Announcement Date 10/15/19 10/12/20 10/25/21 10/24/22 10/9/23 - - -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 1.45 2.08 22.5
Net Cash position 1 - - - 4.26 0.99 - - -
Leverage (Debt/EBITDA) - - - - - -0.4609 x -0.641 x 0.6612 x
Free Cash Flow 1 - - - - -3.27 -2.3 -2 20.4
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share 2 - - - -0.0300 - -0.0300 -0.0300 0.2800
Capex 1 - - - - - 0 - -
Capex / Sales - - - - - 1.82% - -
Announcement Date 10/15/19 10/12/20 10/25/21 10/24/22 10/9/23 - - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2525 GBP
Average target price
1.76 GBP
Spread / Average Target
+597.03%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SAREUM HOLDINGS PLC Stock Sareum Holdings plc
-57.56% 33.71M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.65% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.75% 101B
ARGENX SE Stock argenx SE
+5.71% 23.07B
BIONTECH SE Stock BioNTech SE
-12.60% 22.23B
GENMAB A/S Stock Genmab A/S
-9.70% 18.05B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.17% 16.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.12% 14.07B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.47% 12.35B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SAR Stock
  4. Financials Sareum Holdings plc